G 蛋白偶联受体（GPCRs）是药物研发的重要靶点，但信号转导复杂阻碍了药物开发。研究人员探索了 GPCRs 的偏向性信号传导和细胞内调节剂，发现其在精准医学中具有潜在应用价值，有助于开发更安全有效的药物。 在生命科学和医学领域，药物研发一直是攻克 ...

为解决G蛋白偶联受体(GPCR)中孤儿受体配体鉴定难题，研究人员开发了GzESTY检测技术。该研究通过优化GsGz嵌合体与cAMP生物传感 ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced ...

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...

Addex Therapeutics partner Indivior advances GABAB positive allosteric modulator programme successfully through IND enabling studies: Geneva, Switzerland Tuesday, May 13, 2025, 15 ...

The U.S. biotech company has developed a platform that finds and develops drugs that target special proteins called G protein-coupled receptors (GPCRs). These proteins help pass chemicals from ...